Matthijs Versteegh 6/25/24 Matthijs Versteegh 6/25/24

Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model

$Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy Results From the EPISODE Study$

Matthijs Versteegh 3/25/24 Matthijs Versteegh 3/25/24

Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy Results From the EPISODE Study

Matthijs Versteegh 10/30/23 Matthijs Versteegh 10/30/23

Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries

Matthijs Versteegh 10/30/23 Matthijs Versteegh 10/30/23

Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

Matthijs Versteegh 10/3/23 Matthijs Versteegh 10/3/23

HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead

Matthijs Versteegh 8/14/23 Matthijs Versteegh 8/14/23

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Matthijs Versteegh 8/8/23 Matthijs Versteegh 8/8/23

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Matthijs Versteegh 7/25/23 Matthijs Versteegh 7/25/23

Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale

Matthijs Versteegh 4/19/23 Matthijs Versteegh 4/19/23

The value of health in a cost-effectiveness analysis: theory vs practice

Matthijs Versteegh 2/22/23 Matthijs Versteegh 2/22/23

The economics of patents and innovation in pharma

Matthijs Versteegh 10/11/22 Matthijs Versteegh 10/11/22

Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib

Matthijs Versteegh 8/4/22 Matthijs Versteegh 8/4/22

Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries

Matthijs Versteegh 7/7/22 Matthijs Versteegh 7/7/22

Estimating Quality of Life Decrements in Oncology Using Time to Death

Matthijs Versteegh 4/26/22 Matthijs Versteegh 4/26/22

Correcting for discounting and loss aversion in composite time trade-off

Matthijs Versteegh 4/8/22 Matthijs Versteegh 4/8/22

Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020

Simone Huygens 3/2/22 Simone Huygens 3/2/22

The Net Benefit of Personalized Medicine: a Systematic Literature Review and Regression Analysis

Simone Huygens 12/15/21 Simone Huygens 12/15/21

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

Matthijs Versteegh 10/25/21 Matthijs Versteegh 10/25/21

Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study

Matthijs Versteegh 9/30/21 Matthijs Versteegh 9/30/21

The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa

Matthijs Versteegh 9/1/21 Matthijs Versteegh 9/1/21

105P prognostic value of the NTRK fusion biomarker in the Netherlands

Publications.